PT Millennium Pharmacon International Tbk (SDPC.JK)
IDR 132.0
(0.76%)
IDR 132.0
(0.76%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 33.08 Billion IDR | 35.25% |
| 2022 | 24.46 Billion IDR | 155.6% |
| 2021 | 9.57 Billion IDR | 241.3% |
| 2020 | 2.8 Billion IDR | -64.41% |
| 2019 | 7.88 Billion IDR | -59.47% |
| 2018 | 19.44 Billion IDR | 37.12% |
| 2017 | 14.18 Billion IDR | 27.68% |
| 2016 | 11.1 Billion IDR | -6.73% |
| 2015 | 11.9 Billion IDR | 62.7% |
| 2014 | 7.31 Billion IDR | -28.58% |
| 2013 | 10.24 Billion IDR | 4.05% |
| 2012 | 9.84 Billion IDR | 146.11% |
| 2011 | 4 Billion IDR | 165.46% |
| 2010 | 1.5 Billion IDR | -84.15% |
| 2009 | 9.51 Billion IDR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 5.13 Billion IDR | -37.63% |
| 2024 Q2 | 8.23 Billion IDR | 16.18% |
| 2024 Q1 | 7.09 Billion IDR | 11.54% |
| 2023 Q1 | 5.84 Billion IDR | 839.2% |
| 2023 FY | 33.08 Billion IDR | 35.25% |
| 2023 Q4 | 6.35 Billion IDR | 77.19% |
| 2023 Q3 | 3.58 Billion IDR | -79.26% |
| 2023 Q2 | 17.29 Billion IDR | 195.96% |
| 2022 Q3 | 9.92 Billion IDR | 252.34% |
| 2022 Q4 | 622.31 Million IDR | -93.73% |
| 2022 Q1 | 11.1 Billion IDR | 2611.14% |
| 2022 FY | 24.46 Billion IDR | 155.6% |
| 2022 Q2 | 2.81 Billion IDR | -74.64% |
| 2021 Q2 | 2.42 Billion IDR | 171.71% |
| 2021 FY | 9.57 Billion IDR | 241.3% |
| 2021 Q4 | -442.17 Million IDR | -106.6% |
| 2021 Q3 | 6.7 Billion IDR | 176.93% |
| 2021 Q1 | 890.75 Million IDR | 198.15% |
| 2020 FY | 2.8 Billion IDR | -64.41% |
| 2020 Q4 | -907.58 Million IDR | -552.34% |
| 2020 Q1 | 6.77 Billion IDR | 650.57% |
| 2020 Q2 | -2.92 Billion IDR | -143.16% |
| 2020 Q3 | -139.12 Million IDR | 95.24% |
| 2019 Q2 | 3.74 Billion IDR | -7.42% |
| 2019 FY | 7.88 Billion IDR | -59.47% |
| 2019 Q1 | 4.04 Billion IDR | 79.97% |
| 2019 Q4 | -1.23 Billion IDR | -193.48% |
| 2019 Q3 | 1.31 Billion IDR | -64.87% |
| 2018 Q3 | 5.88 Billion IDR | -26.06% |
| 2018 FY | 19.44 Billion IDR | 37.12% |
| 2018 Q1 | 3.35 Billion IDR | 47.51% |
| 2018 Q2 | 7.95 Billion IDR | 137.4% |
| 2018 Q4 | 2.24 Billion IDR | -61.78% |
| 2017 FY | 14.18 Billion IDR | 27.68% |
| 2017 Q1 | 4.09 Billion IDR | 122.45% |
| 2017 Q2 | 3.88 Billion IDR | -5.16% |
| 2017 Q3 | 3.92 Billion IDR | 1.15% |
| 2017 Q4 | 2.27 Billion IDR | -42.15% |
| 2016 Q1 | 3.16 Billion IDR | 28.68% |
| 2016 FY | 11.1 Billion IDR | -6.73% |
| 2016 Q4 | 1.84 Billion IDR | 1680.63% |
| 2016 Q3 | 103.39 Million IDR | -98.28% |
| 2016 Q2 | 5.99 Billion IDR | 89.68% |
| 2015 Q2 | 4.24 Billion IDR | 102.18% |
| 2015 Q1 | 2.09 Billion IDR | -45.86% |
| 2015 FY | 11.9 Billion IDR | 62.7% |
| 2015 Q4 | 2.45 Billion IDR | -20.83% |
| 2015 Q3 | 3.1 Billion IDR | -26.88% |
| 2014 Q1 | 2.39 Billion IDR | -1.24% |
| 2014 FY | 7.31 Billion IDR | -28.58% |
| 2014 Q3 | 773.54 Million IDR | 184.91% |
| 2014 Q2 | 271.5 Million IDR | -88.66% |
| 2014 Q4 | 3.87 Billion IDR | 401.38% |
| 2013 Q3 | 3.01 Billion IDR | 40.18% |
| 2013 Q2 | 2.14 Billion IDR | -19.3% |
| 2013 Q4 | 2.42 Billion IDR | -19.48% |
| 2013 FY | 10.24 Billion IDR | 4.05% |
| 2013 Q1 | 2.66 Billion IDR | -10.22% |
| 2012 FY | 9.84 Billion IDR | 146.11% |
| 2012 Q3 | 1.93 Billion IDR | 0.0% |
| 2012 Q4 | 2.96 Billion IDR | 53.24% |
| 2011 FY | 4 Billion IDR | 165.46% |
| 2010 FY | 1.5 Billion IDR | -84.15% |
| 2009 FY | 9.51 Billion IDR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 688.49 Billion IDR | 95.194% |
| PT Itama Ranoraya Tbk | 5.19 Billion IDR | -536.492% |
| PT Kimia Farma (Persero) Tbk | -1485.56 Billion IDR | 102.227% |
| PT Soho Global Health Tbk | 371.34 Billion IDR | 91.09% |